Cargando…
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
INTRODUCTION: In nearly all cases, acromegaly is caused by excess GH from a pituitary adenoma, resulting in elevated circulating levels of GH and, subsequently, IGF-1. Treatment goals are to eliminate morbidity and restore the increased mortality to normal rates. Therapeutic strategies aim to minimi...
Autores principales: | Colao, Annamaria, Auriemma, Renata S., Pivonello, Rosario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799266/ https://www.ncbi.nlm.nih.gov/pubmed/26290466 http://dx.doi.org/10.1007/s11102-015-0677-y |
Ejemplares similares
-
Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015) -
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022) -
Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas
por: Auriemma, Renata S., et al.
Publicado: (2019) -
Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment
por: Pirchio, Rosa, et al.
Publicado: (2021) -
Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)